Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
European Urology
|
December 4, 2018
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]
Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
European Urology
|
December 24, 2017
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
Der Urologe. Ausg. A
|
January 15, 2009
[Complete resection of urothelial cancer metastases with curative intent]
J Lehmann, H Suttmann, P Albers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
C Gratzke, M Özgüroğlu, A Peer, et al.
Lancet (London, England)
|
December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
M De Santis, P J Wiechno, J Bellmunt, et al.
European Urology
|
December 4, 2018
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8]
Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
European Urology
|
December 24, 2017
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E Rosenberg, et al.
Der Urologe. Ausg. A
|
January 15, 2009
[Complete resection of urothelial cancer metastases with curative intent]
J Lehmann, H Suttmann, P Albers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study
J N Graff, M Burotto, P C Fong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
C Gratzke, M Özgüroğlu, A Peer, et al.
Lancet (London, England)
|
December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Page
of 9